The short version of analytical characterisation fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-05-10. Anything still debated is marked as such rather than presented as settled.
Melanotan-2 appears on the World Anti-Doping Agency prohibited list within the peptide hormone class, and several national regulators treat it as an unapproved prescription substance. Some countries restrict importation or sale for personal use. Because the compound is widely traded as a research chemical, the practical legal picture differs between jurisdictions and shifts over time. Human safety data covering long periods are limited, and whether repeated pigmentation changes carry any lasting risk to melanocytes remains an open question.
Freeze-dried melanotan-2 is normally kept as a desiccated powder at minus twenty degrees Celsius or lower, shielded from light and moisture. Peptides of this size degrade through hydrolysis, oxidation and deamidation, and each pathway accelerates as temperature and water activity rise. Repeated freeze-thaw cycles promote aggregation and loss of material, so aliquoting a stock solution before freezing is standard laboratory practice. Once dissolved, the solution is markedly less stable than the powder. In laboratory work, solutions are generally refrigerated and used within days rather than kept for months.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or oxidised impurities. Mass spectrometry, most often coupled to liquid chromatography, confirms molecular mass and detects substitutions that chromatography alone may miss. Amino acid analysis and peptide mapping supply additional structural evidence, while nuclear magnetic resonance is reserved for full structural confirmation. Laboratories that examine samples sold online report wide variation in actual content, with some vials containing little or none of the labelled material.
Independent verification is central to quality control because the compound is not produced under pharmaceutical manufacturing standards. Third-party laboratories can measure purity, identity, residual solvents, and microbial contamination, though the scope of testing varies between services. Reported analyses of vendor samples have shown batch-to-batch variation in peptide content and the presence of truncated or oxidized species. How much of this variation reflects synthesis conditions versus storage and shipping is not well characterized. No harmonized reference standard exists for the material as sold.
Handling guidance for melanotan II follows general practice for small synthetic peptides rather than a product-specific monograph. Lyophilized powder is typically kept at minus twenty degrees Celsius or colder, protected from light and moisture, because warmth and humidity accelerate degradation. Once reconstituted, solutions are usually refrigerated and used within a short window, as hydrolysis and microbial growth both become concerns. Repeated freeze-thaw cycles are generally avoided. These conventions come from laboratory peptide chemistry and not from formal stability studies on this specific compound.
Analytical confirmation of identity relies on mass spectrometry, most often coupled to liquid chromatography. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and provides a purity estimate based on peak area. Electrospray ionization mass spectrometry then confirms the expected molecular mass, while tandem mass spectrometry can map the fragment sequence. For research-grade material, these two techniques together form the standard minimum. Purity figures reported by vendors are frequently not traceable to an independent laboratory.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C or below | For the lyophilised powder, desiccated |
| Storage form | Sealed vial, protected from light | Amber glass or foil-wrapped containers |
| Reconstituted stability | Short, refrigerate | Degradation accelerates in solution |
| Typical analytical method | Reversed-phase HPLC with mass spectrometry | Purity assessment plus identity confirmation |
| Common synonyms | Melanotan II, MT-II | Also written melanotan-2 |
Reported observations after unregulated use include shifts in skin pigmentation and, in some accounts, unintended changes to moles and other lesions. Whether these outcomes are causally linked to the compound, and how often they occur, remain open questions because controlled data are scarce. The absence of standardised dosing and verified product purity complicates interpretation. Researchers have called for better surveillance and analytical characterisation of samples obtained outside regulated channels. Conclusions drawn from anecdotal evidence should be treated as provisional.
Melanotan-2 has not received marketing authorisation from major regulatory agencies for any therapeutic indication. Several jurisdictions classify it as a prescription-only medicine or a controlled substance when supplied for human use. Because approved products do not exist, material sold online usually sits outside pharmaceutical supply chains and formal quality oversight. Regulators have issued public notices describing the compound as unapproved. Enforcement varies, and the legal position differs between countries, which complicates any single general statement about its status.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
Regulatory treatment varies by country. In the United States, melanotan-2 is not approved for any indication, and products marketed for human use fall outside the approved drug framework. Some other jurisdictions have placed it under prescription controls or listed it as a prohibited or restricted substance. Online listings frequently describe the material as a research chemical, a category that does not carry the same manufacturing and labelling requirements as approved medicines.
Solid peptide material is generally stable when kept cold and dry. Common practice is storage at -20 degrees Celsius or lower, with desiccant and protection from light. Repeated freeze-thaw cycles and exposure to moisture are associated with degradation, aggregation, or loss of material. Once dissolved, stability depends on solvent, concentration, and temperature, and solutions are usually treated as short-lived unless stability data support longer periods. Handling notes typically emphasise minimising time at ambient temperature.
Identity and purity are assessed with chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the target peptide from related impurities and degradation products, and the resulting retention time is compared against a reference standard. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass. Amino acid analysis or peptide mapping can provide additional sequence-level confirmation when required. Results are only as reliable as the reference materials used alongside them.
Lyophilised peptide powder is comparatively stable when kept dry, cold and protected from light. Once dissolved, the molecule is exposed to hydrolysis, oxidation and microbial growth, and degradation accelerates at higher temperatures and in alkaline solution. Repeated freeze-thaw cycles concentrate solutes and promote aggregation. Handling guidance for research peptides commonly clusters around freezer temperatures for powder and short refrigerated use for reconstituted solutions, with pH control and sterile technique applied throughout.
Verification of a purchased sample requires documentation linking a batch to a certificate of analysis, and that document should be read for the methods used rather than the headline purity figure. A single chromatographic percentage does not establish identity. Independent laboratories can perform identity and content assays, but no such test establishes that a product is suitable for human use. Claims about efficacy rest largely on small, early studies rather than on replicated controlled trials, and that gap remains open.
Identity testing for a cyclic peptide of this size usually relies on reversed-phase high-performance liquid chromatography coupled to mass spectrometry. The mass spectrum confirms molecular weight, while the chromatographic trace indicates the proportion of related impurities. Tandem mass spectrometry can provide sequence-level information when fragmentation data are compared against a reference standard. Nuclear magnetic resonance is sometimes used to confirm the lactam bridge, although it requires more material and greater operator expertise than routine chromatographic methods.
Melanotan II holds no marketing authorisation from the Food and Drug Administration, the European Medicines Agency, the UK Medicines and Healthcare products Regulatory Agency or Australia's Therapeutic Goods Administration. Products sold under that name are treated as unapproved new drugs, and their sale or import is prohibited in several jurisdictions. Other countries classify the peptide as a prescription-only medicine or place it among controlled substances, so the legal position changes with the destination market. No pharmacopoeial monograph supplies an official specification, because the material is not a licensed pharmaceutical. Consequently, products offered online are not manufactured to a shared public standard.
The peer-reviewed record is dominated by small early-phase studies, case reports and pharmacovigilance summaries rather than large randomised trials. Papers typically examine tanning response, receptor selectivity or patterns of reported adverse events. Many note that participants obtained the peptide outside a clinical setting, which limits verification of composition and administered amount. Reported events vary widely, and causality is frequently unclear because the identity and purity of self-sourced material are unknown. Open questions include whether repeated melanocortin receptor stimulation produces cumulative effects, and how often label claims match actual content.
=== Etymology === The name estradiol derives from estra-, Gk. οἶστρος (oistros, literally meaning "verve or inspiration"), which refers to the estrane steroid ring system, and -diol, a chemical term and suffix indicating that the compound is a type of alcohol bearing two hydroxyl groups.
The European Monitoring Centre for Drugs and Drug Addiction reports that the retail price of brown heroin varies from €14.5 per gram in Turkey to €110 per gram in Sweden, with most European countries reporting typical prices of €35–40 per gram. The price of white heroin is reported only by a few European countries and ranged between €27 and €110 per gram. The United Nations Office on Drugs and Crime claims in its 2008 World Drug Report that typical US retail prices are US$172 per gram.
Sir Joseph John Thomson (18 December 1856 – 30 August 1940) was a British physicist. He received the 1906 Nobel Prize in Physics "in recognition of the great merits of his theoretical and experimental investigations on the conduction of electricity by gases." In 1897, he showed that cathode rays were composed of previously unknown negatively charged particles (now called electrons), which he calculated must have bodies much smaller than atoms and a very large charge-to-mass ratio. The electron was the first subatomic particle to be discovered. Thomson is credited with finding the first evidence for isotopes of a stable (non-radioactive) element in 1912, as part of his exploration into the composition of canal rays (positive ions). His experiments to determine the nature of positively charged particles, with Francis William Aston, were the first use of mass spectrometry and led to the development of the mass spectrograph. Thomson was an influential teacher, and seven of his students went on to win Nobel Prizes: Ernest Rutherford (Chemistry 1908), Lawrence Bragg (Physics 1915), Charles Barkla (Physics 1917), Francis Aston (Chemistry 1922), Charles Thomson Rees Wilson (Physics 1927), Owen Richardson (Physics 1928) and Edward Appleton (Physics 1947). His son, George Paget Thomson, shared the 1937 Nobel Prize in Physics with Clinton Davisson "for their experimental discovery of the diffraction of electrons by crystals".
In medicinal chemistry, parallel artificial membrane permeability assay (PAMPA) is a method which determines the permeability of substances from a donor compartment, through a lipid-infused artificial membrane into an acceptor compartment. A multi-well microtitre plate is used for the donor and a membrane/acceptor compartment is placed on top; the whole assembly is commonly referred to as a “sandwich”. At the beginning of the test, the drug is added to the donor compartment, and the acceptor compartment is drug-free. After an incubation period which may include stirring, the sandwich is separated and the amount of drug is measured in each compartment. Mass balance allows calculation of drug that remains in the membrane.
== Total costs to the US == Obesity has been cited as a contributing factor to approximately 100,000–400,000 deaths in the United States per year (including increased morbidity in car accidents) and has increased health care use and expenditures, costing society an estimated $117 billion in direct (preventive, diagnostic, and treatment services related to weight) and indirect (absenteeism, loss of future earnings due to premature death) costs. This exceeds health-care costs associated with smoking or problem drinking and, by one estimate, accounts for 6% to 12% of national health care expenditures in the United States (although another estimate states the figure is between 5% and 10%). The Medicare and Medicaid programs bear about half of this cost. Annual hospital costs for treating obesity-related diseases in children rose threefold, from US$35 million to US$127 million, in the period from 1979 to 1999, and the inpatient and ambulatory healthcare costs increased drastically by US$395 per person per year. These trends in healthcare costs associated with pediatric obesity and its comorbidities are staggering, urging the Surgeon General to predict that preventable morbidity and mortality associated with obesity may surpass those associated with cigarette smoking. Furthermore, the probability of childhood obesity persisting into adulthood is estimated to increase from approximately twenty percent at four years of age to approximately eighty percent by adolescence, and it is likely that these obesity comorbidities will persist into adulthood.
Sources: en.wikipedia.org
Conduction velocity The speed at which an action potential travels along a nerve fiber. It is influenced by factors such as axon diameter and myelination. Consciousness A state of awareness of self and the environment. In neuroscience, it involves the coordinated activity of multiple brain regions, particularly the thalamocortical system. Corpus callosum The largest white matter structure in the brain, consisting of a thick band of axons that connects the left and right cerebral hemispheres. Cortical column A vertically organized group of neurons in the cerebral cortex that processes the same type of information, such as orientation or location in space. It is a basic functional unit of the cortex. Cortical plasticity The ability of the cerebral cortex to adapt and reorganize in response to experience, learning, or injury. Corticospinal tract A major descending pathway from the motor cortex to the spinal cord that mediates voluntary motor control, especially fine movements of the limbs. Creutzfeldt–Jakob disease (CJD) A rare and fatal neurodegenerative disorder caused by misfolded prion proteins. It leads to rapid cognitive decline, motor dysfunction, and ultimately death. Critical period A developmental window during which the nervous system is particularly sensitive to certain environmental stimuli, crucial for proper development of functions such as vision and language. Cross modal plasticity The ability of one sensory modality to reorganize and compensate in another’s absence (e.g., visual cortex being recruited for touch in individuals who are blind).
Asprey (1919–2005), American nuclear chemist known for actinide, lanthanide, rare-earth and fluorine chemistry Alán Aspuru-Guzik (born 1976), Mexican computational chemist known for variational quantum eigensolver Francis William Aston (1877–1945), British chemist and physicist known for mass spectroscopy, 1922 Nobel Prize in Chemistry Bengt Aurivillius (1918–1994), Swedish chemist known for his research in metal and mixed oxides. Karin Aurivillius (1920–1982), Swedish chemist who determined the crystal structures of many mercury compounds Amedeo Avogadro (1776–1856), Italian chemist and physicist, discovered Avogadro's law as a copmponent of noted for his contribution to molecular theory
In 1999 its parent company reorganized and changed its name to PE Corporation, and the PE Biosystems Group (formerly again became publicly traded, as a tracking stock of its parent, along with its sister tracking stock company, Celera Genomics. In 2000 the parent became Applera Corporation. The Applied Biosystems name also returned that year, in the name change of the tracking stock from PE Biosystems Group to Applera Corporation-Applied Biosystems Group, an S&P 500 company, which remains as a publicly traded operating group within Applera Corp., along with its sibling operating group, Applera Corporation-Celera Group. Applera derives its name from the combination of its two component groups' names, Appl(iedCel)era In November 2008, a merger between Applied Biosystems and Invitrogen was finalized "creating a global leader in biotechnology reagents and systems". The new company was called Life Technologies.
== Research and development == In November 2013, Discovery Laboratories began its phase II clinical program of aerosolized KL4 since U.S. Food and Drug Administration (FDA) had cleared the investigational new drug (IND) application. The phase II consists of two steps to evaluate the safety and tolerability of the drug and determine the optimal dose for premature infants with respiratory distress syndrome (RDS) In October 2013, Discovery Laboratories received the agreement of updating Surfaxin (lucinactant) Intratracheal Suspension from the U.S. Food and Drug Administration (FDA) to prevent respiratory distress syndrome (RDS) in premature infants. In September 2012, Discovery Laboratories started the four research projects to explore the KL4 surfactant technology for acute lung injury (ALI). These projects are funded through government-sponsored, biodefense-related initiatives under the Project Bioshield Act of 2004 and the Pandemic and All-Hazards Preparedness Act of 2006.
labelling Also tagging. The chemical attachment of a highly selective substance, known as a label, tag, or probe, to a particular cell, protein, amino acid, or other molecule of interest, either naturally or artificially, in vivo or in vitro. Natural labelling is a primary mechanism by which biomolecules specifically identify and interact with other biomolecules; important examples include methylation, acetylation, phosphorylation, and glycosylation. Labelling is also a common laboratory technique, where the label is typically a reactive derivative of a naturally fluorescent compound (e.g. green fluorescent protein), dye, enzyme, antibody, radioactive molecule, or any other substance that makes its target distinguishable in some way. The labelled targets are thereby rendered distinct from their unlabelled surroundings, allowing them to be detected, identified, quantified, or isolated for further study.
Sources: en.wikipedia.org
The lyophilised solid is best kept cold, dry and dark, typically at minus twenty degrees Celsius. Moisture and repeated warming cycles are the main causes of degradation. Solutions prepared from the powder are less stable and are normally used quickly.
Reversed-phase liquid chromatography assesses purity, while mass spectrometry confirms molecular mass and detects sequence errors. Amino acid analysis and peptide mapping add structural detail. These techniques are complementary rather than interchangeable.
It is listed as a prohibited peptide hormone by the World Anti-Doping Agency. No medicines regulator has approved it for human use. Import and sale rules vary by country.
The lyophilized powder is generally held at minus twenty degrees Celsius or below, away from light and moisture. Reconstituted solutions are typically refrigerated and used quickly. These practices derive from general peptide handling rather than a formal stability study.